Effect of empagliflozin on cardiovascular death in subgroups by age: results from EMPA-REG OUTCOME

被引：0
|
作者：
Ridderstrale, M. [1 ]
Fitchett, D. [2 ]
Kis, S. Giljanovic [3 ]
Woerle, H. J. [4 ]
Mattheus, M. [4 ]
Zinman, B. [5 ]
Inzucchi, S. [6 ]
机构：
[1] Steno Diabet Ctr, Gentofte, Denmark
[2] Univ Toronto, St Michaels Hosp, Div Cardiol, Toronto, ON, Canada
[3] Eli Lilly Suisse SA, Representat Off, Zagreb, Croatia
[4] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[5] Univ Toronto, Lunenfeld Tanenbaum Res Inst, Mt Sinai Hosp, Div Endocrinol, Toronto, ON, Canada
[6] Yale Univ, Endocrinol Sect, Sch Med, New Haven, CT USA
来源：
EUROPEAN HEART JOURNAL | 2016年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5803
引用
收藏
页码：1192 / 1192
页数：1
相关论文
共 50 条
  • [21] EMPA-REG OUTCOME: cardiovascular outcome trials in diabetes come of age
    Krentz, Andrew J.
    CARDIOVASCULAR ENDOCRINOLOGY, 2015, 4 (04): : 115 - 116
  • [22] EMPA-REG Outcome: results that question
    Pouchain, Denis
    EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE, 2016, 27 (128): : 278 - 282
  • [23] CONSISTENT EFFECT OF EMPAGLIFLOZIN ON COMPOSITE OUTCOMES RELATED TO HEART FAILURE: RESULTS FROM EMPA-REG OUTCOME
    Inzucchi, Silvio E.
    Zinman, Bernard
    McGinniss, Jennifer
    Schnee, Janet
    George, Jyothis
    Fitchett, David
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 1656 - 1656
  • [24] Empagliflozin in Resistant Hypertension: Findings From the Empa-reg Outcome Trial
    Ferreira, Joao Pedro
    Fitchett, David
    Ofstad, Anne Pernille
    Kraus, Bettina J.
    Wanner, Christoph
    Zwiener, Isabella
    Lauer, Sabine
    George, Jyothis T.
    Rossignol, Patrick
    Zannad, Faiez
    CIRCULATION, 2019, 140
  • [25] Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trial
    Verma, Subodh
    Leiter, Lawrence A.
    Zinman, Bernard
    Sharma, Abhinav
    Mattheus, Michaela
    Fitchett, David
    George, Jyothis
    Ofstad, Anne Pernille
    Kosiborod, Mikhail N.
    Wanner, Christoph
    Inzucchi, Silvio E.
    ESC HEART FAILURE, 2021, 8 (04): : 2603 - 2607
  • [26] Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME®
    Kaku, Kohei
    Lee, Jisoo
    Mattheus, Michaela
    Kaspers, Stefan
    George, Jyothis
    Woerle, Hans-Juergen
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    Mortelmans, J.
    Strivay, M.
    Vereecken, G.
    Keymeulen, B.
    Lamkanfi, F.
    CIRCULATION JOURNAL, 2017, 81 (02) : 227 - +
  • [27] Relationship between Hypoglycaemia (Hypo), Outcomes and Empagliflozin (EMPA) Treatment Effect in EMPA-REG OUTCOME
    Zinman, Bernard
    Fitchett, David H.
    Mattheus, Michaela
    Wanner, Christoph
    George, Jyothis T.
    Vedin, Ola
    Inzucchi, Silvio E.
    Johansen, Odd Erik
    DIABETES, 2019, 68
  • [28] MEDIATORS OF THE EMPAGLIFLOZIN TREATMENT EFFECT ON KIDNEY OUTCOMES IN THE EMPA-REG OUTCOME TRIAL
    Jardine, M.
    Wanner, C.
    Nangaku, M.
    Kraus, B.
    Zinman, B.
    Mattheus, M.
    Hantel, S.
    Schumacher, M.
    Ohneberg, K.
    Schmoor, C.
    Inzucchi, S. E.
    NEPHROLOGY, 2021, 26 : 19 - 19
  • [29] Improvements in Liver Enzymes with Empagliflozin in the EMPA-REG OUTCOME Trial
    Sattar, Naveed
    Fitchett, David H.
    Hantel, Stefan
    George, Jyothis T.
    Zinman, Bernard
    DIABETES, 2018, 67
  • [30] Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME®
    Bernard Zinman
    Silvio E. Inzucchi
    Christoph Wanner
    Uwe Hehnke
    Jyothis T. George
    Odd Erik Johansen
    David Fitchett
    Diabetologia, 2018, 61 : 1522 - 1527
12345